

Actinium Pharmaceuticals, Inc.




Disease-Free Survival – Iomab-B Phase 1/2 Results


Excerpt from study 1432 provided for reference purposes

Study 1432: Disease-Free Survival in Patients with R/R AML

Kaplan-Meier Survival Curve for Disease-Free Survival – AML Subjects with Relapsed, Primary Refractory, or Relapsed/Refractory Disease



Study 1432: A Phase 1 Study Combining Escalating Dose of Radiolabeled BC8 (Anti-CD45) Antibody with Fludarabine, LowDose TBI, PBSC Infusion and Post-transplant Immunosuppression with Cyclosporine and Mycophenolate Mofetil to Establish Mixed or Full Donor Chimerism for Elderly Patients with Advanced Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome N=36. Excerpted from clinical study report for reference purposes.



Actinium
Pharmaceuticals, Inc.



Thank You
ATNM: NYSE AMERICAN